When was Repros Therapeutics founded?

Repros Therapeutics was founded in 1987 and raised its 1st funding round 22 years after it was founded.

Where is Repros Therapeutics located?

Repros Therapeutics is headquartered in The Woodlands, United States.

How many employees does Repros Therapeutics have?

As of Mar 01, 2026, the latest employee count at Repros Therapeutics is 10 - 49.

Is Repros Therapeutics a funded company?

Repros Therapeutics is a funded company, having raised an undisclosed amount across 3 funding rounds to date. The company's 1st funding round was a $***** Post IPO round, raised on 2009.

When was the latest funding round of Repros Therapeutics?

Repros Therapeutics' latest funding was a $***** Post IPO round on Sep 18, 2012, with participation from 0 investor.

What is the annual revenue of Repros Therapeutics?

Annual revenue of Repros Therapeutics is less than $1M as on Dec 31, 2016

Where does Repros Therapeutics rank among its competitors?

Repros Therapeutics ranks 19th amongst 39 active competitors, of which 8 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Agile Therapeutics, which secured $275K in Feb, 2024.

Who are the top competitors of Repros Therapeutics?

Repros Therapeutics' top competitors include Agile Therapeutics, Marius Pharmaceuticals and Peptonic Medical. Among them, Agile Therapeutics secured the most recent funding round in February, 2024.

Repros Therapeutics - 2026 Company Profile, Funding, Competitors & Financials

Company Details

Repros Therapeutics, formerly Zonogen, develops oral small molecule drugs for male and female reproductive health. It has two main clinical programs. The first one Enclomiphene is an oral small molecule compound targeting secondary male hypogonadism and is currently in phase II trials. In addition, the company is developing Proellex, a selective blocker of the progesterone receptor. that is in early clinical trials for uterine fibroids and endometriosis.

Key Metrics

Founded Year

1987

Location

The Woodlands, United States

Stage

Acqui-Hired

Latest Funding Round

Post IPO, Sep 18, 2012, $*****

Investors

Alta Partners & 4 more

Ranked

19^th among 39 active competitors

Annual Revenue

$0 - $1M as on Dec 31, 2016

Employee Count

10 - 49 as on Mar 01, 2026

Similar Companies

Agile Therapeutics & 59 more

View Repros Therapeutics' full profile

Repros Therapeutics is associated with 2 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Repros Therapeutics Inc. CIN: 897075 , United States, Active	Aug 19, 1987	$0 - $1M (As on Dec 31, 2016)	-	-
REPROS THERAPEUTICS INC CIN: 760233274 , United States, Active		-	-	-

Repros Therapeutics has raised funding over 3 rounds. Its first funding round was on 2009. Repros Therapeutics has 5 institutional investors.

Here is the list of recent funding rounds of Repros Therapeutics:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Sep 18, 2012	2127565	Post IPO	8586634	8786557	3053813	8388395
Nov 11, 2009	9369353	Post IPO	5027570	2971055	5545250	5521398
2009	5684	Post IPO	5959	8858	2382	New Enterprise Associates

Access funding benchmarks and valuations. Sign up today!

View details of Repros Therapeutics's funding rounds and investors

Repros Therapeutics' employee count trend

Repros Therapeutics has 10 - 49 employees as of Mar 26. Here is Repros Therapeutics's employee count trend over the years:

Employee count trend for Repros Therapeutics

Uncover Repros Therapeutics' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Repros Therapeutics include Agile Therapeutics, Marius Pharmaceuticals and Peptonic Medical. Here is the list of Top 10 competitors of Repros Therapeutics, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Agile Therapeutics 1997, Princeton (United States), Acquired	Developer of therapeutics for women healthcare	$124M	Aisling Capital, Kaiser Permanente Ventures ... & 11 others	58/100
2nd	Marius Pharmaceuticals 2017, Raleigh (United States), Series B	Developer of an proprietary oral testosterone replacement therapy platform	$32.6M	Shah Capital	49/100
3rd	Peptonic Medical 2009, Vaxjo (Sweden), Public	Developer of therapeutics for the treatment of vaginal atrophy	$1.06M	Aggregate Media, Almi Invest & 1 others	46/100
4th	Auxilium Pharmaceuticals 1999, Philadelphia (United States), Acquired	Developer of therapeutics and drug-device combinations for urology and sexual health	$43M	New Leaf Venture Partners, Aisling Capital ... & 8 others	45/100
5th	Creative Medical Technologies 2011, Phoenix (United States), Public	Stem-cell based therapeutics for male and female reproductive health	-	-	43/100
6th	Microchips Biotech 1999, Lexington (United States), Acquired	Microchip-based implants for drug delivery	$90.7M	Medtronic, Flybridge Capital Partners & 8 others	42/100
7th	Asarina Pharma 2006, Umea (Sweden), Series A	Developer of drugs for the premenstrual dysphoric disorder (PMDD)	$28M	Idinvest Partners, Ergomed & 7 others	40/100
8th	Xanodyne Pharmaceuticals 2001, Florence (United States), Acqui-Hired	Developer of drugs for women's health and pain management	$214M	AIG Investments, Aisling Capital & 9 others	38/100
9th	Prescient Therapeutics 1986, South Melbourne (Australia), Public	Targeted small molecule inhibitors of Ras and Akt pathway for the treatment of cancer	$3M	-	38/100
10th	Bionovo 2002, Emeryville (United States), Public	Develops botanically-derived drugs for menopausal symptoms and cancer	$16.4M	Centrecourt Asset Management, Silicom Ventures ... & 1 others	38/100
19th	Repros Therapeutics 1987, The Woodlands (United States), Acqui-Hired	Oral small molecule drugs for reproductive health	-	Alta Partners, New Enterprise Associates & 3 others	32/100